Recro Pharma Inc

Recro Pharma Inc. is a revenue-generating specialty pharmaceutical company based in Malvern, Pennsylvania. With 78 employees, the company focuses on developing non-opioid products for pain management in hospitals and ambulatory care settings. Recro Pharma has achieved $77 million in annual revenue. The company's primary product candidate is a proprietary injectable form of meloxicam, an NSAID currently in Phase II clinical trials for treating moderate to severe pain. Recro Pharma also has Dex-IN, a proprietary intranasal formulation of dexmedetomidine, which successfully completed a Phase II clinical trial for post-operative pain. The company plans to pursue approval for Dex-IN in peri-procedural pain. If approved, Dex-IN would be the first peri-procedural pain drug in its class. Recro Pharma's non-opioid product candidates aim to provide an effective alternative to opioids, avoiding common side effects like addiction, constipation, and respiratory depression while maintaining strong pain relief. The company believes its products could address the need for safer pain management options for the millions undergoing surgical procedures annually. For more information about Recro Pharma Inc. and its product pipeline, please visit recropharma.com.